Huisheng Bio's GLP-1R/GCGR dual-target agonist P052 injection, a subsidiary of Sihuan Pharmaceutical, was approved for IND for type 2 diabetes and obesity.
Recently, Huisheng Biologics, a subsidiary of Sihuan Pharmaceutical, announced that its GLP-1R/GCGR dual-target agonist P052 injection has been approved by the National Drug Administration (NMPA) for clinical trial approval (IND) and is intended to be used to treat type 2 diabetes and obesity. This progress marks an important breakthrough in Huisheng Bio's innovative research and development in the field of metabolic diseases, and also provides new potential treatment options for diabetics and obese people around the world.
1. The core advantages of P052 injection
P052 injection is a new dual-target agonist of GLP-1R (glucagon-like peptide-1 receptor) and GCGR (glucagon receptor). By simultaneously activating the GLP-1R and GCGR signaling pathways, it plays a role in synergistically lowering glucose, weight loss and metabolism improvement. Compared with existing single-target GLP-1R agonists, P052 may have more significant effects in weight loss and blood sugar control.
| index | P052 Injection | Single-target GLP-1R agonist |
|---|---|---|
| Target | GLP-1R/GCGR dual target | GLP-1R single target |
| Lowering sugar effects | More significant | medium |
| Weight loss effect | More potential | limited |
| Metabolic improvement | comprehensive | part |
2. Current status of the global diabetes and obesity market
Diabetes and obesity are major public health issues around the world. According to the International Diabetes Alliance (IDF), the number of diabetes patients worldwide has reached 537 million in 2021, and is expected to increase to 783 million by 2045. The obese population is equally large and closely related to diabetes.
| area | Diabetic patients (millions) | Obesity rate (%) |
|---|---|---|
| China | 141 | 16.4 |
| USA | 32 | 42.4 |
| Europe | 61 | 23.3 |
| worldwide | 537 | 13.1 |
3. Research and development progress and market potential of P052 injection
The approval of IND of P052 injection is an important milestone for Huisheng Bio in the field of metabolic diseases. The drug has completed preclinical studies and the results show that it has good safety and effectiveness. Next, Huisheng Bio will launch a Phase I clinical trial to further verify the pharmacokinetics and safety of P052 in the human body.
From a market perspective, the market size of GLP-1 drugs is growing rapidly. Take Novo Nordisk's Semaglutide as an example, its global sales in 2022 have exceeded US$10 billion. As a dual-target agonist, P052 is expected to gain a place in future market competition.
| Drug name | Target | Sales in 2022 (US$ 100 million) |
|---|---|---|
| Smeglute | GLP-1R | 108 |
| Dulasugar peptide | GLP-1R | 74 |
| liraglutide | GLP-1R | 36 |
4. Industry competitive landscape and future prospects
At present, multiple GLP-1R/GCGR dual-target agonists have entered the clinical stage around the world, including Eli Lilly's Retatrutide and Innovent Biologics' IBI362. The addition of P052 injection will further enrich the R&D pipeline in this field.
Huisheng Bio said that it will accelerate the clinical trial of P052 in the future and explore its potential applications in other metabolic diseases. At the same time, Sihuan Pharmaceutical will also lay the foundation for the future listing of P052 with its mature commercialization capabilities.
With the continued growth of people with diabetes and obesity, the market demand for GLP-1R/GCGR dual-target agonists will continue to expand. The development progress of P052 injection provides new hope for patients and adds important bargaining chips to the competition among Chinese innovative pharmaceutical companies in the global metabolic disease field.
en
